RFK Jr.’s committee approves manufacture of peptides he uses
▼ Summary
– An FDA committee voted to endorse removing restrictions on manufacturing four peptides for human use, with votes on three more scheduled.
– The vote was sharply divided and occurred despite a lack of evidence regarding the safety and effectiveness of these peptides.
– Health and Human Services Secretary Robert F. Kennedy Jr., a peptide enthusiast, had taken steps months earlier to ensure this outcome.
– Peptides are short chains of amino acids (10–20 long), differing from longer proteins, and some like insulin are specifically processed to send signals to cells.
– Many peptides result from the breakdown of larger proteins and may trigger physiological responses, but understanding their effects can take decades, with evidence often limited to cell studies.
A committee convened by the Food and Drug Administration (FDA) has voted to recommend easing restrictions on the manufacture of peptides for human use, a long-anticipated decision that aligns with the preferences of Health and Human Services Secretary Robert F. Kennedy Jr., a known peptide enthusiast. The panel’s vote on Thursday was sharply divided, approving the removal of limits on four peptides, with votes on three additional peptides scheduled for Friday. This recommendation comes despite a persistent lack of evidence regarding the safety and efficacy of these compounds.
The outcome was telegraphed months in advance, as Kennedy took deliberate steps to steer the process toward this result. Peptides, like proteins, are chains of amino acids, but they are distinguished by their shorter length,typically 10 to 20 amino acids, compared to the hundreds or thousands found in proteins. Some peptides, such as insulin, are produced through the targeted processing of larger proteins and interact with specific receptors to send signals to cells. However, many peptides are simply byproducts of biological complexity, arising when larger proteins break down into predictable fragments. Some of these fragments, being short and flexible, may bind to other proteins and trigger physiological responses, while others are digested and recycled without any notable effect.
Understanding a peptide’s origin and its downstream effects can require decades of research. In many cases, scientists have only cell-level data showing what happens when a peptide is applied to cultured cells, with no insight into its effects on a living organism. This evidentiary gap is notorious in drug development, where promising candidates often fail when tested in intact animals. The committee’s decision, therefore, raises significant questions about the balance between regulatory flexibility and public health safeguards.
(Source: Ars Technica)
